
    
      A Phase 1, randomized, double-blind, placebo-controlled dose escalation trial of three dose
      cohorts of 10 subjects (A: 10mg, B: 25mg, and C: 50mg). Dose escalation will not occur until
      safety data through Day 8 is reviewed by the Safety Review Committee (SRC). The study will
      consist of a twenty-eight day screening period and 8-hour clinic stay. Follow-up visits will
      occur on Days (Â±3 days) 4, 8, 15, 30, 45, 60, 90, and 120 for all cohorts. Pharmacokinetics
      (PK) and anti-drug antibodies will be tested.
    
  